Approval · Notice of Compliance 36539 · 2025
WEGOVY: Notice of Compliance 36539
Issued December 10, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 36539
- Date
- December 10, 2025
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- Wegovy (semaglutide injection) is indicated for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)
- With conditions
- Yes (NOC/c)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| WEGOVY | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 0.5 MG per ML
- SEMAGLUTIDE 1 MG per ML
- SEMAGLUTIDE 2 MG per ML
- SEMAGLUTIDE 2.27 MG per ML
- SEMAGLUTIDE 3.2 MG per ML
- SEMAGLUTIDE 0.68 MG per ML
- SEMAGLUTIDE 1.34 MG per ML